Pre-operative atorvastatin therapy to decrease the systemic inflammatory response after coronary artery bypass grafting

Journal of International Medical Research

Volumn 36, Issue 6, 2008, Pages 1248-1254

  Dereli, Y ^a   Ege, E ^a   Kurban, S ^a   Narin, Cüneyt ^a   Sarigul A ^a   Yeniterzi, M ^a  

^a SELCUK UNIVERSITY   (Turkey)

Author keywords

Atorvastatin; Cardiopulmonary bypass; Coronary artery bypass grafting; Statins; Systemic inflammatory response syndrome

Indexed keywords

ATOR; ATORVASTATIN; C REACTIVE PROTEIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PYRROLE DERIVATIVE;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIOPULMONARY BYPASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; INFLAMMATION; INTENSIVE CARE UNIT; LENGTH OF STAY; MALE; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PROTEIN BLOOD LEVEL; RISK REDUCTION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; BLOOD; CLINICAL TRIAL; METHODOLOGY; MIDDLE AGED; POSTOPERATIVE COMPLICATION; PREOPERATIVE CARE; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY ARTERY BYPASS; FEMALE; HEPTANOIC ACIDS; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; PYRROLES; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT OUTCOME;

EID: 59649114142     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000803600611     Document Type: Article

References (23)

1. Chello M, Patti G, Candura D, et al: Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery, Crit Care Med 2006; 34: 660-667.
2. Casey LC. Role of cytokines in the pathogenesis of cardiopulmonary-induced multisystem organ failure. Ann Thorac Surg 1993; 56(5 suppl): S92-S96.
3. Partrick DA, Moore EE, Fullerton DA, et al: Cardiopulmonary bypass renders patients at risk for multiple organ failure via early neutrophil priming and the neutrophil disability. J Surg Res 1999; 86: 42-49.
4. Chan AW, Bhatt DL, Chew DP, et al: Relation of inflammation and benefir of statins after percutaneous coronary interventions. Circulations 2003; 107; 1750-1756.
5. Poldermans D, Bax JJ, Kertai MD, et al: Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation 2003; 107: 1848-1851.
6. Pasceri V, Patti G, Nusca A, et al: for the ARMYDA Investigators: Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2004; 110: 674-678.
7. Otsuji S, Shibata H, Umeda M: Turbidimetric immunoassay of serum C-reactive protein. Clin Chem 1982; 28: 2121-2124.
8. Sacks FM, Pfeffer MA, Moye LA, et al: for the Cholesterol and Recurrent Events Trial Investigators: The effects of pravastatin on coronary events after myocardial infarction in coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009
9. Heechen C Hamm CW, Laufs U, et al: for the Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators: Withdrawal of statins increases event rates in patients with acute coronary syndrome. Circulation 2002; 105: 1446-1452.
10. Giomarelli P, Scolletta S, Borrelli E, et al: Myocardial and lung injury after cardiopulmonary bypass: role of interleukin (IL)-10. Ann Thorac Surg 2003; 76: 117-123.
11. Rangel-Frausto MS, Pittet D, Costigan M, et al: The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995; 273: 117-123.
12. Kilbourn RG, Belloni P: Endothelial cell production of nitrogen oxides in response to interferon γ in combination with tumor necrosis factor, interleukin-1, or endotoxin. J Natl Cancer Inst 1990; 82: 772-776.
13. Jialal I, Stein D, Balis D, et al: Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor theraphy on high sensitiver C-reactive protein levels. Circulation 2001; 103: 1933-1935.
14. Horwich TB, Maclellan WR, Fonarow GC: Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardial 2004; 43: 642-648.
15. Ridker PM, Rifai N, Clearfield M, et al: for the Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators: Measurement of C-reactive protein for the targeting of statin theraphy in the primary prevention of acute coronary events. N Engl J Med 2001; 344: 1959-1965.
16. Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest 2002; 110: 285-288.
17. Naidu BV, Woolley SM, Farivar AS, et al: Simvastatin ameliorates injury in an reperfusion. J Thorac Cardiovasc surg 2003; 126: 482-489.
18. Lefer AM, Campbell B, Shin YK, et al: Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation 1999; 100: 178-184.
19. Chello M, Mastroroberto P, Patti G, et al: Simvastatin attenuates leucocyte-endothelial interactions after coronary revascularisation with cardiopulmonary bypass. Heart 2003; 89: 538-543.
20. Dotoni MI, Elnicki DM, Jain AC, et al: Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting. Am J Cardiol 2000; 86: 1128-1130.
21. Pascual DA, Arribas JM, Tornel PL, et la: Preoperative statin therapy and troponin T predict early complications of coronary artery surgery. Ann Thorac Surg 2006; 81: 78-83.
22. Florens E, Salvi S, Peynet J, et al: Can statins reduce the inflammatory response to cardiopulmonary bypass? A clinical study. J Card Surg 2001; 16: 232-239.
23. Plenge JK, Hernandez TL, Weil KM, et al: Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002; 106: 1447-1452.